Additionally, more investigations are needed to precisely define the prognostic value of other parameters, namely pre-treatment levels of Hb and LDH, performance status, analgesic intake, bone or lymph node metastases, the intensity of uptake in the pre-treatment PET/CT, and pre-treatment PSA level, as well as the dose and number of cycles of the therapy. The gene discussed is KLK3; the disease is metastatic malignant neoplasm in the lymph nodes.